US · IMRX · BIOTECHNOLOGY
Immuneering Corporation (IMRX) intrinsic value and stock valuation
$3.38as of 2026-11-21 · Mkt cap 163.72M
Data updated · price as of 2026-11-21
- P/E
- Pro
- P/B
- Pro
- P/S
- Pro
Price history
Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.
Immuneering Corporation DCF and intrinsic value
InvestorsCraft values IMRX with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from IMRX’s statements →
Immuneering Corporation Graham Number
The Graham Number is not defined for negative earnings or book value. Guide · Calculator →
How the business is doing
Fiscal 2019–2025, USD
Is it expensive?
Each multiple against its own 15-year range, or against peers where no history is available
Peers
Same-industry companies, ranked by market cap
- Zura Bio Limited (ZURA) $0.93
- Assembly Biosciences, Inc. (ASMB) $22.19
- Enanta Pharmaceuticals, Inc. (ENTA) $7.62
- Foghorn Therapeutics Inc. (FHTX) $1.72
- Entrada Therapeutics, Inc. (TRDA) $4.35
- Pyxis Oncology, Inc. (PYXS) $1.81
- Arcturus Therapeutics Holdings Inc. (ARCT) $7.45
- Tenaya Therapeutics, Inc. (TNYA) $0.29
Peer comparison
The peer comparison table is shown only to users with a Pro subscription.
Financials
Statements by fiscal year
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $320K | $2.08M |
| Operating income | -$-59.38M | -$-64.07M | -$-58.41M | -$-51.74M | -$-33.89M |
| Net income | -$-56.02M | -$-61.04M | -$-53.47M | -$-50.51M | -$-33.54M |
| EPSd | -$-1.27M | -$-2.04M | -$-1.88M | -$-1.91M | -$-1.27M |
| Operating cash flow | -$-45.34M | -$-55M | -$-48.97M | -$-44.1M | -$-30.85M |
| Capital expenditure | -$-140K | -$-80K | -$-340K | -$-740K | -$-60K |
| Free cash flow | -$-45.49M | -$-55.08M | -$-49.31M | -$-44.84M | -$-30.91M |
| Total assets | $232M | $52.7M | $102.6M | $122.4M | $166.7M |
| Total debt | $3.82M | $4.16M | $4.46M | $4.84M | $5.36M |
| Net debt | -$-124.82M | -$-31.98M | -$-54.94M | -$-67.8M | -$-69.52M |
| Total equity | $218.5M | $41.4M | $90.6M | $109.9M | $156M |
| Cash and short-term investments | $172.8M | $36.1M | $85.7M | $105.5M | $149.2M |
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $320K | $2.08M |
| Cost of revenue | $700K | $0.00 | $0.00 | $160K | $1.15M |
| Gross profit | -$-700K | $0.00 | $0.00 | $160K | $930K |
| Research and development expenses | $42.1M | $48M | $41.6M | $36.3M | $26.5M |
| Selling, general and administrative expenses | $17.3M | $16.1M | $16.8M | $15.6M | $8.27M |
| Other expenses | -$-670K | $30K | $30K | $30K | $0.00 |
| Operating expenses | $58.7M | $64.1M | $58.4M | $51.9M | $34.8M |
| Cost and expenses | $59.4M | $64.1M | $58.4M | $52.1M | $36M |
| Interest income | $3.04M | $2.59M | $3.61M | $1.01M | $170K |
| Interest expense | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Depreciation and amortization | $700K | $390K | $350K | $280K | $160K |
| Ebitda | -$-55.33M | -$-63.69M | -$-58.06M | -$-51.47M | -$-33.68M |
| Operating income | -$-59.38M | -$-64.07M | -$-58.41M | -$-51.74M | -$-33.89M |
| Total other income/expenses, net | $3.35M | $3.03M | $4.94M | $1.23M | $40K |
| Income before tax | -$-56.02M | -$-61.04M | -$-53.47M | -$-50.51M | -$-33.84M |
| Income tax expense | $0.00 | $0.00 | $0.00 | $0.00 | -$-310K |
| Net income | -$-56.02M | -$-61.04M | -$-53.47M | -$-50.51M | -$-33.54M |
| Weighted average shares outstanding | $44M | $30M | $28.4M | $26.4M | $26.3M |
| Weighted average diluted shares outstanding | $44M | $30M | $28.4M | $26.4M | $26.3M |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash and short-term investments | $172.8M | $36.1M | $85.7M | $105.5M | $149.2M |
| Net receivables | $0.00 | $0.00 | $0.00 | $10K | $250K |
| Inventory | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total current assets | $176.3M | $39.6M | $89.1M | $108.8M | $152.3M |
| Property, plant and equipment, net | $4.26M | $4.79M | $5.4M | $5.78M | $6.13M |
| Goodwill and intangible assets | $7.01M | $7.04M | $7.07M | $7.1M | $7.14M |
| Long-term investments | $0.00 | $0.00 | $0.00 | $0.00 | $1M |
| Total non-current assets | $55.7M | $13.1M | $13.5M | $13.6M | $14.4M |
| Total assets | $232M | $52.7M | $102.6M | $122.4M | $166.7M |
| Accounts payable | $1.54M | $1.96M | $2.11M | $3.15M | $1.39M |
| Short-term debt | $400K | $340K | $300K | $380K | $270K |
| Deferred revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total current liabilities | $10.1M | $7.5M | $7.85M | $8.05M | $5.63M |
| Long-term debt | $3.43M | $3.82M | $4.16M | $4.46M | $5.09M |
| Deferred revenue, non-current | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total non-current liabilities | $3.43M | $3.82M | $4.16M | $4.46M | $5.09M |
| Capital lease obligations | $3.82M | $4.16M | $4.46M | $4.84M | $5.36M |
| Total liabilities | $13.5M | $11.3M | $12M | $12.5M | $10.7M |
| Common stock | $60K | $30K | $30K | $30K | $30K |
| Retained earnings | -$-280.32M | -$-224.3M | -$-163.26M | -$-109.79M | -$-59.27M |
| Accumulated other comprehensive income (loss) | $80K | $0.00 | -$0.00 | -$-30K | -$-50K |
| Total equity | $218.5M | $41.4M | $90.6M | $109.9M | $156M |
| Total investments | $44.2M | $0.00 | $26.3M | $32.9M | $75.3M |
| Total debt | $3.82M | $4.16M | $4.46M | $4.84M | $5.36M |
| Net debt | -$-124.82M | -$-31.98M | -$-54.94M | -$-67.8M | -$-69.52M |
Cash flow statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Net income | -$-56.02M | -$-61.04M | -$-53.47M | -$-50.51M | -$-33.54M |
| Depreciation and amortization | $700K | $390K | $350K | $800K | $160K |
| Stock-based compensation | $0.00 | $6.5M | $5.73M | $0.00 | $1.8M |
| Change in working capital | $3.82M | -$-930K | -$-970K | $1.72M | $900K |
| Accounts receivable | $0.00 | $0.00 | $10K | $230K | $280K |
| Inventory | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Accounts payable | -$-400K | -$-110K | -$-1.11M | $1.76M | -$-130K |
| Net cash provided by operating activities | -$-45.34M | -$-55M | -$-48.97M | -$-44.1M | -$-30.85M |
| Investments in property, plant and equipment | -$-140K | -$-80K | -$-340K | -$-740K | -$-60K |
| Acquisitions, net | $0.00 | $0.00 | $0.00 | $0.00 | $70K |
| Net cash used for investing activities | -$-88.74M | $26.4M | $7.3M | $41.8M | -$-75.62M |
| Common stock issued | $226.6M | $4.24M | $28.2M | $20K | $120.3M |
| Common stock repurchased | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Dividends paid | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net cash used for financing activities | $226.6M | $5.3M | $28.4M | $20K | $144.3M |
| Net change in cash | $92.5M | -$-23.26M | -$-13.23M | -$-2.25M | $37.8M |
| Cash at end of period | $128.7M | $36.1M | $59.4M | $72.6M | $74.9M |
| Operating cash flow | -$-45.34M | -$-55M | -$-48.97M | -$-44.1M | -$-30.85M |
| Capital expenditure | -$-140K | -$-80K | -$-340K | -$-740K | -$-60K |
| Free cash flow | -$-45.49M | -$-55.08M | -$-49.31M | -$-44.84M | -$-30.91M |
Line items
Line items
Line items
About Immuneering Corporation
Immuneering Corporation is a biopharmaceutical company dedicated to developing novel therapeutic candidates in the fields of oncology (cancer) and neuroscience. Leading its clinical development efforts are two key drug candidates: IMM-1-104, a dual-MEK inhibitor intended for the treatment of various cancers, including pancreatic, melanoma, colorectal, and non-small cell lung cancer, specifically those driven by RAS and/or RAF gene mutations. The second is IMM-6-415, which is being developed to treat solid tumors. Beyond these advanced-stage programs, Immuneering's early-stage pipeline includes five oncology initiatives aimed at components of the MAPK or mTOR signaling pathways, along with two neuroscience programs, all currently in the discovery phase. Founded in 2008, Immuneering Corporation is headquartered in Cambridge, Massachusetts. It was formerly a subsidiary of Teva Pharmaceutical Industries Limited.
- CEO
- Benjamin J. Zeskind
- Employees
- 37
- Beta
- 0.37
Explore
Frequently asked questions
What is the intrinsic value of Immuneering Corporation (IMRX)?
InvestorsCraft does not currently publish an intrinsic value for IMRX. How the IC value is calculated.
Is IMRX undervalued?
InvestorsCraft does not publish an undervaluation signal for IMRX at this time.
How is the intrinsic value calculated?
InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.
How often is this page updated?
Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.